Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Glucuronidation in humans. Pharmacogenetic and developmental aspects.

de Wildt SN, Kearns GL, Leeder JS, van den Anker JN.

Clin Pharmacokinet. 1999 Jun;36(6):439-52. Review.

PMID:
10427468
2.

UDP-glucuronosyltransferases and clinical drug-drug interactions.

Kiang TK, Ensom MH, Chang TK.

Pharmacol Ther. 2005 Apr;106(1):97-132. Epub 2005 Jan 12. Review.

PMID:
15781124
3.
4.

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J.

Pharmacol Ther. 2014 Jan;141(1):92-116. doi: 10.1016/j.pharmthera.2013.09.002. Epub 2013 Sep 27. Review.

PMID:
24076267
5.

Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.

Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B.

Toxicol Lett. 2000 Mar 15;112-113:333-40. Review.

PMID:
10720749
6.

Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation.

Burchell B, Brierley CH, Rance D.

Life Sci. 1995;57(20):1819-31. Review.

PMID:
7475929
7.

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.

Nagar S, Remmel RP.

Oncogene. 2006 Mar 13;25(11):1659-72. Review.

PMID:
16550166
8.
9.

Ontogeny of hepatic glucuronidation; methods and results.

Krekels EH, Danhof M, Tibboel D, Knibbe CA.

Curr Drug Metab. 2012 Jul;13(6):728-43. Review.

PMID:
22452455
10.

Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases.

Zhou J, Zhang J, Xie W.

Curr Drug Metab. 2005 Aug;6(4):289-98. Review.

PMID:
16101569
11.

Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases.

Batt AM, Magdalou J, Vincent-Viry M, Ouzzine M, Fournel-Gigleux S, Galteau MM, Siest G.

Clin Chim Acta. 1994 May;226(2):171-90. Review.

PMID:
7923812
12.

A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years.

Radominska-Pandya A, Bratton S, Little JM.

Curr Drug Metab. 2005 Apr;6(2):141-60. Review.

PMID:
15853765
13.

Drug glucuronidation in clinical psychopharmacology.

Liston HL, Markowitz JS, DeVane CL.

J Clin Psychopharmacol. 2001 Oct;21(5):500-15. Review.

PMID:
11593076
14.

Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

Miners JO, McKinnon RA, Mackenzie PI.

Toxicology. 2002 Dec 27;181-182:453-6. Review.

PMID:
12505351
15.

Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).

Strassburg CP, Kalthoff S, Ehmer U.

Crit Rev Clin Lab Sci. 2008;45(6):485-530. doi: 10.1080/10408360802374624 . Review.

PMID:
19003600
16.

Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.

Guillemette C.

Pharmacogenomics J. 2003;3(3):136-58. Review.

PMID:
12815363
17.

Glucuronidation and the UDP-glucuronosyltransferases in health and disease.

Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, Ritter JK.

Drug Metab Dispos. 2004 Mar;32(3):281-90. Review.

18.

High-throughput screening technologies for drug glucuronidation profiling.

Trubetskoy O, Finel M, Trubetskoy V.

J Pharm Pharmacol. 2008 Aug;60(8):1061-7. doi: 10.1211/jpp.60.8.0012. Review.

PMID:
18644198
19.

Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Tukey RH, Strassburg CP.

Annu Rev Pharmacol Toxicol. 2000;40:581-616. Review.

PMID:
10836148
20.

Modulation of UDP-glucuronosyltransferase activity by protein-protein association.

Ishii Y, Takeda S, Yamada H.

Drug Metab Rev. 2010 Feb;42(1):145-58. doi: 10.3109/03602530903208579. Review.

PMID:
19817679

Supplemental Content

Support Center